Megan L. Mills

Megan L. Mills

Auto-generated profile, based on publicly available information

Megan L. Mills

Cancer Research UK Scotland Institute, Glasgow, UK

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 November 2025 in Nature
Verified
Journal Article
Open access
PDF file
MWMark White
Mark White
MMMegan L. Mills
Megan L. Mills
LMLaura M. Millett
Laura M. Millett
KGKathryn Gilroy
Kathryn Gilroy
YHYourae Hong
Yourae Hong
OSOwen Sansom
Owen Sansom
The colorectal epithelium is rapidly renewing, with remarkable capacity to regenerate following injury. In colorectal cancer (CRC), this regenerative capacity can be co-opted to drive epithelial plasticity. Although oncogenic MAPK signalling in CRC is common, with frequent mutations of both KRAS (40–50%) and BRAF (10%) 1 , inhibition of this pathway typically drives resistance clinically. Here, given the development of KRAS inhibitors and licensing of BRAF inhibitor combinations 2–4 , we have interrogated key mechanisms of resistance to these agents in advanced preclinical CRC models. We show that oncogenic MAPK signalling induces epithelial-state changes in vivo, driving adoption of a regenerative/revival stem-like population, whereas inhibition leads to rapid transcriptional remodelling of both Kras -mutant and Braf- mutant tumours, favouring a WNT-associated, canonical stem phenotype. This drives acute therapeutic resistance in Kras -driven and delayed resistance in Braf -driven models. Where plasticity is restrained, such as in early metastatic disease, or through targeting ligand-dependent WNT pathway Rnf43 mutations, marked therapeutic responses are observed. This explains the super response to BRAF + EGFR-targeted therapies previously observed in a BRAF–RNF43 co-mutant patient population, highlighting the criticality of cellular plasticity in therapeutic response. Together, our data provide clear insight into the mechanisms underpinning resistance to MAPK-targeted therapies in CRC. Moreover, strategies that aim to corral stem cell fate, restrict epithelial plasticity or intervene when tumours lack heterogeneity may improve therapeutic efficacy of these agents.

29 February 2024 in Cancer Research Communications
Verified
Journal Article
Open access
PDF file
RFRana Fetit
Rana Fetit
AMAlistair S. McLaren
Alistair S. McLaren
MWMark White
Mark White
MMMegan L. Mills
Megan L. Mills
JFJohn Falconer
John Falconer
CSColin W. Steele
Colin W. Steele
Neutrophils are a highly heterogeneous cellular population. However, a thorough examination of the different transcriptional neutrophil states between health and malignancy has not been performed. We utilized single-cell RNA sequencing of human and murine datasets, both publicly available and independently generated, to identify neutrophil transcriptomic subtypes and developmental lineages in health and malignancy. Datasets of lung, breast, and colorectal cancer were integrated to establish and validate neutrophil gene signatures. Pseudotime analysis was used to identify genes driving neutrophil development from health to cancer. Finally, ligand–receptor interactions and signaling pathways between neutrophils and other immune cell populations in primary colorectal cancer and metastatic colorectal cancer were investigated. We define two main neutrophil subtypes in primary tumors: an activated subtype sharing the transcriptomic signatures of healthy neutrophils; and a tumor-specific subtype. This signature is conserved in murine and human cancer, across different tumor types. In colorectal cancer metastases, neutrophils are more heterogeneous, exhibiting additional transcriptomic subtypes. Pseudotime analysis implicates IL1β/CXCL8/CXCR2 axis in the progression of neutrophils from health to cancer and metastasis, with effects on T-cell effector function. We propose that the emergence of metastatic-specific neutrophil subtypes is driven by the IL1β/CXCL8/CXCR2 axis, with the evolution of different transcriptomic signals that impair T-cell function at the metastatic site. Thus, a better understanding of neutrophil transcriptomic programming could optimize immunotherapeutic interventions into early and late interventions, targeting different neutrophil states. Significance: We identify two recurring neutrophil populations and demonstrate their staged evolution from health to malignancy through the IL1β/CXCL8/CXCR2 axis, allowing for immunotherapeutic neutrophil-targeting approaches to counteract immunosuppressive subtypes that emerge in metastasis.

6 June 2025 in Research Square
Verified
Preprint
Open access
PDF file
YHYourae Hong
Yourae Hong
SSSusanti Susanti
Susanti Susanti
MMMegan L. Mills
Megan L. Mills
KGKathryn L. Gilroy
Kathryn L. Gilroy
ZHZedong Hu
Zedong Hu
STSabine Tejpar
Sabine Tejpar
In the colonic epithelium, fetal programming is induced by Yes-associated protein (YAP) signaling, which is associated with tumorigenesis and progression in colorectal cancer (CRC). While CRC was long considered a WNT driven disease, here we show that fetal programmed cells with activated YAP signaling can arise independently of WNT activation. Fetal programmed cells, in the presence of hyper- or hypo-activated WNT, have different characteristics and are associated with poor relapse. Furthermore, using various mouse models, we demonstrated the conserved characteristics of two different fetal programmed cell states with different WNT activation, which can be switched from a hyperactivated to hypoactivated WNT state based on genetic alteration, particularly Kras mutation. Taken together, these data redefine the key determinants of epithelial cell states in colorectal cancer and integrate emerging preclinical biology into a robust landscape of states observed in human and mouse.

29 February 2024
Verified
Other
Open access
PDF file
RFRana Fetit
Rana Fetit
AMAlistair S. McLaren
Alistair S. McLaren
MWMark White
Mark White
MMMegan L. Mills
Megan L. Mills
JFJohn Falconer
John Falconer
CSColin W. Steele
Colin W. Steele
Figure S1. Neutrophil proportions in KPN CRC models and in integrated mouse neutrophil dataset.


29 February 2024
Verified
Other
Open access
RFRana Fetit
Rana Fetit
AMAlistair S. McLaren
Alistair S. McLaren
MWMark White
Mark White
MMMegan L. Mills
Megan L. Mills
JFJohn Falconer
John Falconer
CSColin W. Steele
Colin W. Steele
Characterization of neutrophil signatures and lineages in health and PTs. A, Uniform Manifold Approximation and Projection for Dimension (UMAP) plot of healthy neutrophils grouped by tissue type. BM: healthy bone marrow, SP: healthy spleen, L: healthy lung, BL: healthy blood. B, UMAP plots of healthy and tumor-derived neutrophils grouped by tissue type and Seurat clusters (0–15). BM: healthy bone marrow, SP: healthy spleen, L: healthy lung, BL: healthy blood, L_AC: lung adenocarcinoma, KPN: colorectal cancer with Kras, Trp53 and Notch mutations. C, UMAP plot of neutrophils in mouse breast cancer model. WT: healthy breast tissue, PyMT: polyomavirus middle-T oncoprotein tumor. D and E, Scoring of H_enriched and T_enriched neutrophil signatures. F, UMAP plot of neutrophils in mouse colorectal cancer model. All neutrophils are tumor-derived. G and H, H_enriched and T_enriched signatures in colorectal cancer (CRC). I, UMAP plot of human NSCLC neutrophils. Blood: blood-derived, tumor: tumor-derived. J and K, H_enriched and T_enriched signatures NSCLC. L, UMAP plot of human breast carcinoma (BC) neutrophils. Most neutrophils are tumor-derived. M and N, H_enriched and T_enriched signatures in breast carcinoma. O–R, Unsupervised pseudotime analysis of neutrophils in mouse and human datasets. Lineages in the individual datasets are numbered. S–V,Il1β/IL1β is differentially expressed at the end of tumor-specific lineages. W–Z, Estimated smoothers for Il1β/IL1β expression over pseudotime across the different lineages.